Immune activation and HIV persistence: implications for curative approaches to HIV infection.
about
Animal models in HIV cure researchImpact of antiretroviral therapy (ART) timing on chronic immune activation/inflammation and end-organ damageLoss of Function of Intestinal IL-17 and IL-22 Producing Cells Contributes to Inflammation and Viral Persistence in SIV-Infected Rhesus MacaquesHIV Cell-to-Cell Spread Results in Earlier Onset of Viral Gene Expression by Multiple Infections per CellPerspectives for immunotherapy: which applications might achieve an HIV functional cure?Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory AgentsDissecting How CD4 T Cells Are Lost During HIV InfectionEffects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized TrialLatency reversal and viral clearance to cure HIV-1.A pilot study of brisk walking in sedentary combination antiretroviral treatement (cART)- treated patients: benefit on soluble and cell inflammatory markers.Reduction of HIV persistence following transplantation in HIV-infected kidney transplant recipientsSystemic effects of inflammation on health during chronic HIV infectionLevels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation.Plasma IP-10 Concentrations Correlate Positively with Viraemia and Inversely with CD4 Counts in Untreated HIV InfectionMucosal SIV Vaccines Comprising Inactivated Virus Particles and Bacterial Adjuvants Induce CD8(+) T-Regulatory Cells that Suppress SIV-Positive CD4(+) T-Cell Activation and Prevent SIV Infection in the Macaque Model.Immunologic strategies for HIV-1 remission and eradication.Immunity to HIV in Early LifeLimited HIV infection of central memory and stem cell memory CD4+ T cells is associated with lack of progression in viremic individuals.Factors associated with CD8+ T-cell activation in HIV-1-infected patients on long-term antiretroviral therapyHIV infection of monocytes-derived dendritic cells inhibits Vγ9Vδ2 T cells functionsMathematical model of the Tat-Rev regulation of HIV-1 replication in an activated cell predicts the existence of oscillatory dynamics in the synthesis of viral componentsThe effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation.Influence of age at virologic control on peripheral blood human immunodeficiency virus reservoir size and serostatus in perinatally infected adolescentsHIV controllers with different viral load cutoff levels have distinct virologic and immunologic profiles.Using the pathogenic and nonpathogenic nonhuman primate model for studying non-AIDS comorbidities.Cross-Sectional Analysis of Selected Genital Tract Immunological Markers and Molecular Vaginal Microbiota in Sub-Saharan African Women, with Relevance to HIV Risk and Prevention.HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trialNew insights into type I interferon and the immunopathogenesis of persistent viral infections.Hospitalization Rates and Reasons Among HIV Elite Controllers and Persons With Medically Controlled HIV Infection.Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells.Brugia malayi Antigen (BmA) Inhibits HIV-1 Trans-Infection but Neither BmA nor ES-62 Alter HIV-1 Infectivity of DC Induced CD4+ Th-Cells.Higher Levels of Osteoprotegerin and Immune Activation/Immunosenescence Markers Are Correlated with Concomitant Bone and Endovascular Damage in HIV-Suppressed Patients.Effects of Fecal Microbial Transplantation on Microbiome and Immunity in Simian Immunodeficiency Virus-Infected MacaquesHIV-1 Structural Proteins Serve as PAMPs for TLR2 Heterodimers Significantly Increasing Infection and Innate Immune Activation.Elite Control, Gut CD4 T Cell Sparing, and Enhanced Mucosal T Cell Responses in Macaca nemestrina Infected by a Simian Immunodeficiency Virus Lacking a gp41 Trafficking Motif.During Stably Suppressive Antiretroviral Therapy Integrated HIV-1 DNA Load in Peripheral Blood is Associated with the Frequency of CD8 Cells Expressing HLA-DR/DP/DQContinuous Antigenic Stimulation of DO11.10 TCR Transgenic Mice in the Presence or Absence of IL-1β: Possible Implications for Mechanisms of T Cell Depletion in HIV DiseaseElevated Abundance, Size, and MicroRNA Content of Plasma Extracellular Vesicles in Viremic HIV-1+ Patients: Correlations With Known Markers of Disease Progression.Interleukin-21 combined with ART reduces inflammation and viral reservoir in SIV-infected macaquesHIV-1 Env Glycoprotein Phenotype along with Immune Activation Determines CD4 T Cell Loss in HIV Patients.
P2860
Q26853069-13975DA8-3B13-4B6A-B0BC-A9FA917ECC32Q27014077-6EB89A3D-C6C0-47AD-A8BD-A4B7B1C87303Q27316093-16D3BB01-78E2-4BDD-BDEF-58BAD08E6491Q27681313-E8D6A2D3-4A98-4D57-9871-11AF5AE3B20CQ28078726-017C76AF-CBB8-46C5-A3ED-73D3610CFB66Q28079455-148BFFF8-E32B-4EDC-ACC7-E97D736E208CQ28274045-CE0ED34B-A27F-4AAC-8B29-DF9BB10C0AD1Q28552729-CCCF760C-4A90-4781-B238-01DE298B17BFQ30248766-12203AB1-A6F6-4B18-891F-A53E2AB720AFQ30365593-91A0AF1C-6A9A-4CDD-BAEE-56B15A8AAE73Q33575261-7CB80620-A1C3-4D28-9E51-D6363CD8DA23Q33577551-DBF5C99F-6888-4CCE-8B4F-2C71A98FE651Q33585386-99B5F932-F9D1-43A8-80B8-BBF58F9B106BQ33668482-57D9549B-0DB5-46E4-8D13-FE207A0936A2Q33820903-DC7EE336-7550-4FE9-8DD3-51A2C4CCF965Q33896523-640EF90F-FBF1-43A2-8A24-2AC71C7233E0Q34033051-03C2F00F-D616-4B65-B560-6D469025E361Q34105477-50A6630B-65B1-4A14-B1D9-17B2FEC7079AQ34206123-D84D59DF-8A7B-4C03-AD2D-1D28BAF7F271Q34395668-1E8BDD5A-0363-4248-8B16-DFBF512EA69CQ35004179-3C6D523D-1C5B-4DA0-976F-AAA7E448D287Q35030011-A2DAA156-70EF-4FE9-88D5-643364C0C479Q35072975-90C91295-A26F-4CAA-9A35-28FB58669921Q35102172-C1C04789-535C-4836-9CCE-94E1251C2489Q35204909-A4EE7AC7-FE7A-4D0F-8BF8-D5E5570B2EACQ35548029-CEBA83FF-E648-4FE9-9D0D-C679C0159416Q35552889-25A984B4-AD18-4139-94E8-A559AC981523Q35648751-0966A569-F754-4EFB-B88E-166163212274Q35661912-A2BE1359-49E0-4DD2-99E0-2695C24BA3DAQ35833324-524A268C-028D-465B-8190-B28D3A225E60Q35903597-A14ACB83-772F-4C2A-8B3E-EFDFAEA359CEQ35935297-8CA10B48-9FE2-401F-A55E-12DE07A0F439Q35943919-0FD0E691-4291-4AD8-AAFD-82A8C5D77463Q35970108-CE5BCF0F-5999-4144-B3FE-98E9E1EB6481Q36086229-B04B00AD-B344-4F38-B87D-86502AE1AB16Q36106294-BAC99CA4-A0B1-47D1-AEE6-90BEA35D492AQ36177047-39711D9F-1EFB-4BB7-BD48-38715ABFB233Q36228320-1F2BAFE1-9293-4153-ADCB-AFC47C0F8E2EQ36335882-6DF7B72C-9359-4A5E-9D35-A241B9157290Q36553805-62ED91FF-3F3E-4D5E-A159-90EF00334F53
P2860
Immune activation and HIV persistence: implications for curative approaches to HIV infection.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Immune activation and HIV pers ...... e approaches to HIV infection.
@ast
Immune activation and HIV pers ...... e approaches to HIV infection.
@en
Immune activation and HIV pers ...... e approaches to HIV infection.
@nl
type
label
Immune activation and HIV pers ...... e approaches to HIV infection.
@ast
Immune activation and HIV pers ...... e approaches to HIV infection.
@en
Immune activation and HIV pers ...... e approaches to HIV infection.
@nl
prefLabel
Immune activation and HIV pers ...... e approaches to HIV infection.
@ast
Immune activation and HIV pers ...... e approaches to HIV infection.
@en
Immune activation and HIV pers ...... e approaches to HIV infection.
@nl
P2860
P356
P1476
Immune activation and HIV pers ...... e approaches to HIV infection.
@en
P2093
Daniel C Douek
Nichole R Klatt
P2860
P304
P356
10.1111/IMR.12065
P577
2013-07-01T00:00:00Z